{
    "nctId": "NCT05931042",
    "briefTitle": "Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review",
    "officialTitle": "Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review",
    "overallStatus": "COMPLETED",
    "conditions": "HER2+ Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1209,
    "primaryOutcomeMeasure": "Pathological Complete Response (pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with breast cancer that was found to be HER2 positive were included\n* Only patients who underwent neoadjuvant therapy were included\n* All cytotoxic chemotherapy regimens were considered eligible for this systematic review given that the same drugs were given at the same dose in every trial.\n\nExclusion Criteria:\n\n* Patients with metastatic breast cancer were not included in the systematic review\n* Results from adjuvant therapy were excluded from this study.\n* Only the most recent publication (and the most informative) was included if numerous publications of the same trial were retrieved or if there was a case mix between publications.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}